Project Grant R01NS140100

Award Date 1/1/25
Completion Date 12/31/29
Dollars Obligated $459K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38163, USA
Similar Awards
This $604,795 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research to investigate the role of complement-mediated inflammation in exacerbating stroke outcomes in mice with type 2 diabetes. The research aims to determine the functional role of P-selectin and anaphylatoxin receptors in promoting transmigration of peripheral myeloid...
This Project Grant award in the amount of $1,023,404 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the role of cerebrovascular O-GlcNAcylation in predisposing diabetics to stroke, worsening stroke-induced neurovascular injury, and impairing functional recovery after stroke. The award, granted to the University of South Carolina and effective from September 26, 2024 to August 31, 2025, will fund in vitro...
This federal Project Grant award, valued at $853,135.00, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to define the role of complement C3A receptor signaling in exacerbating acute post-ischemic brain injury and long-term neurological dysfunction following stroke. The research aims to demonstrate that inhibiting...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA Program 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders, provides $192,500 to the University of Utah to investigate the role of endothelial cell sphingolipid metabolism in acute ischemic stroke outcomes in mice. The research aims to (1) determine whether interventions targeting cerebral endothelial cells could improve stroke outcomes, and (2) test a...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $422,572 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of red blood cells in stroke-related hyperglycemia. The research project aims to characterize how acute hyperglycemia following an ischemic...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $423,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the Augusta University Research Institute, Inc. The objective is to develop and evaluate engineered exosomes carrying neuron-targeting peptides and a therapeutic protein (neuroglobin) for treating ischemic stroke. The research will: 1) characterize the engineered exosomes and assess their...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,223,140 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of Chicago to test a novel biopharmaceutical agent, SANGUINATE, that aims to mitigate cerebral infarct growth in acute ischemic stroke. The goal is to evaluate SANGUINATE's ability to boost collateralization and deliver oxygen to ischemic brain tissue, potentially reducing...
The University of Rhode Island Research Office received a $413,729 Project Grant award on September 22, 2023 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The funding will support research to investigate the molecular links between stroke, the actin cytoskeleton, and Alzheimer's disease pathogenesis. The proposed work will use induced...
This $377,875 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to develop engineered extracellular microvesicles (MVs) that can co-deliver mitochondria and a therapeutic heat shock protein (HSP27) to protect the blood-brain barrier (BBB) in a mouse model of stroke. The goal is to determine if this approach...
This $221,120 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research focused on improving neural progenitor cell survival and migration to enhance neurovascular communication and promote recovery after stroke. The key objectives are to investigate the potential of adult central nervous system endothelial cells to express...

This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, funds research to investigate a novel pharmacological approach to mitigate neurovascular complications associated with stroke in diabetic patients. With a total award value of $459,111, the University of Tennessee Health Science Center will conduct comprehensive in vivo and in vitro studies to explore the underlying mechanisms by which a small-molecule SERCA2 activator, CDN1163, can restore calcium homeostasis and attenuate endoplasmic reticulum stress, mitochondrial dysfunction, inflammation, and oxidative stress in diabetic stroke. This 5-year project aims to elucidate how targeting dysfunctional SERCA2 can alleviate the heightened risk of brain injury, blood-brain barrier leakage, edema, and poor recovery outcomes experienced by stroke patients with type 2 diabetes.

Generated 4/8/25, 4:19 AM